



Małgorzata Górską-Ciebiada¹ , Maciej Ciebiada² 

¹Department of Propaedeutics of Lifestyle Diseases, Medical University of Lodz, Poland

²Department of General and Oncological Pneumology, Medical University of Lodz, Poland

Depressive Symptoms, Cognitive Function and Vitamin D Levels in the Oldest-Old Patients with Type 2 Diabetes

Introduction

The oldest-old population (aged 85 or older) is growing fast and there is a need to improve geriatric care. Many individuals in later life experience diabetes mellitus (DM) and depression; and both could be risk factors for dementia and mild cognitive impairment (MCI) [1]. Depression and diabetes have recently become a focus of research [1, 2]. The present study explores the association between the level of vitamin D, which regulates the nervous system and brain [3], and the prevalence of depressive symptoms, MCI and their comorbidity in patients aged ≥ 85 years with type 2 diabetes (T2D).

Methods

A cross-sectional study was conducted among T2D patients aged 85 or older, recruited from an outpatient diabetology clinic. The participants were assessed with the Montreal Cognitive Assessment (MoCA) for MCI and the Geriatric Depression Scale (GDS-30). The serum levels of 25-hydroxyvitamin D were assessed

using ELISA. Detailed data was collected including sociodemographic, clinical, and biochemical parameters. Comparison between groups was done using ANOVA, followed by post-hoc test. Statistica 13.1 (StatSoft, Poland) was used for analysis.

Results

Clinical data were collected from 81 T2D patients, (73.6% female; mean age 87.3 ± 2.6 years). MCI was diagnosed in 21 (25.9%) subjects, depressive symptoms in 12 (14.8%); comorbid cognitive impairment and depression in 16 (19.8%). Thirty-two (39.5%) subjects had no psychiatric problems. The patients with comorbid cognitive impairment and depression were significantly more likely to be female ($p < 0.001$), single ($p = 0.003$), smokers ($p = 0.04$), older ($p = 0.03$), with a higher number of co-morbidities ($p < 0.001$), retinopathy ($p = 0.006$), hyperlipidemia ($p < 0.001$), cardiovascular diseases ($p < 0.001$), and with higher HbA1c level (67 ± 18.5 mmol/L, $p < 0.001$), compared to controls.

ANOVA followed by a *post hoc* test found serum 25-hydroxyvitamin D level was significantly decreased in patients with depressive symptoms (16.48 ± 5.12 ng/mL, $p = 0.025$) and MCI subjects (16.54 ± 3.98 ng/mL, $p = 0.002$) compared to controls (22.28 ± 5.92 ng/mL). The lowest concentration was noted in patients with diabetes who had comorbid MCI and depressive symptoms (14.12 ± 3.29 ng/mL, $p < 0.001$) (Fig. 1).

Correlation analysis showed a significant negative relationship between vitamin D and HbA1c levels in the comorbid cognitive impairment and depression

Address for correspondence:

dr hab. n. med. prof. UM Małgorzata Górską-Ciebiada,
The Department of Propaedeutics of Lifestyle Diseases,
Medical University of Lodz

63 Jaracza Street, 90-251 Lodz, Poland

Tel: +48 42 2725978

e-mail: malgorzata.gorska-ciebiada@umed.lodz.pl

Clinical Diabetology 2024, 13; 2: 124-125

DOI: [10.5603/cd.99634](https://doi.org/10.5603/cd.99634)

Received: 3.03.2024 Accepted: 4.03.2024

Early publication date: 19.03.2024




Figure 1. Serum 25-Hydroxyvitamin D Levels (ng/mL) in the Oldest-Old Patients with Type 2 Diabetes. Dep — patients with depressive symptoms; MCI — patients with mild cognitive impairment; MCI and Dep — patients with comorbid depressive symptoms and MCI; Controls — patients without depressive symptoms and MCI. Values are expressed by mean \pm standard deviation; * # \$ indicate difference between groups and controls, respectively. The ANOVA test followed by *post-hoc* test was used to test for significant differences. A p-value of less than 0.05 was considered statistically significant.

group ($r = -0.83$, $p < 0.001$), the depressive group ($r = -0.74$, $p = 0.006$), and in controls ($r = -0.63$, $p < 0.001$). In patients with comorbid cognitive impairment and depression, 25-hydroxyvitamin D level negatively correlated with GDS-30 score ($r = -0.87$, $p < 0.001$) and positively correlated with MoCA score ($r = 0.81$, $p < 0.001$).

Discussion

Our data indicates comorbidity of MCI, depression and diabetes in the diabetic population over 85 years. Our study showed that lower vitamin D levels were associated with a higher prevalence of MCI and depressive symptoms, as well as higher HbA1c levels, lower MoCA scores and a higher GDS-30 score. In line with

other studies [4, 5] we propose that vitamin D may be a potential protective factor for cognitive impairment and comorbid depression in patients with type 2 diabetes. Further prospective studies are needed to evaluate the influence of vitamin D supplementation on the development of dementia or depression in the oldest-old population.

Article information

Ethical approval

The study was conducted in accordance with the Declaration of Helsinki, and approved by the independent local Ethics Committee of Medical University of Lodz

Funding

The study was supported by nonprofit grant of Medical University of Lodz No: 503/8-072-04/503-81-001.

Conflict of interest

The authors declare no conflict of interest.

REFERENCES

- Ehtewish H, Arredouani A, El-Agnaf O. Diagnostic, Prognostic, and Mechanistic Biomarkers of Diabetes Mellitus-Associated Cognitive Decline. *Int J Mol Sci.* 2022; 23(11), doi: [10.3390/ijms23116144](https://doi.org/10.3390/ijms23116144), indexed in Pubmed: [35682821](https://pubmed.ncbi.nlm.nih.gov/35682821/).
- Zhang H, Xing Y, Zhang Y, et al. Association between depression and quality of life in older adults with type 2 diabetes: A moderated mediation of cognitive impairment and sleep quality. *J Affect Disord.* 2023; 340: 17–24, doi: [10.1016/j.jad.2023.07.105](https://doi.org/10.1016/j.jad.2023.07.105), indexed in Pubmed: [37506770](https://pubmed.ncbi.nlm.nih.gov/37506770/).
- Lasoń W, Jantas D, Leśkiewicz M, et al. The Vitamin D Receptor as a Potential Target for the Treatment of Age-Related Neurodegenerative Diseases Such as Alzheimer's and Parkinson's Diseases: A Narrative Review. *Cells.* 2023; 12(4), doi: [10.3390/cells12040660](https://doi.org/10.3390/cells12040660), indexed in Pubmed: [36831327](https://pubmed.ncbi.nlm.nih.gov/36831327/).
- Gómez-Oliva R, Geribaldi-Doldán N, Domínguez-García S, et al. Vitamin D deficiency as a potential risk factor for accelerated aging, impaired hippocampal neurogenesis and cognitive decline: a role for Wnt/ β -catenin signaling. *Aging (Albany NY).* 2020; 12(13): 13824–13844, doi: [10.18632/aging.103510](https://doi.org/10.18632/aging.103510), indexed in Pubmed: [32554862](https://pubmed.ncbi.nlm.nih.gov/32554862/).
- Chen Rh, Zhao Xh, Gu Z, et al. Serum levels of 25-hydroxyvitamin D are associated with cognitive impairment in type 2 diabetic adults. *Endocrine.* 2014; 45(2): 319–324, doi: [10.1007/s12020-013-0041-9](https://doi.org/10.1007/s12020-013-0041-9), indexed in Pubmed: [23982512](https://pubmed.ncbi.nlm.nih.gov/23982512/).